Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases

BACKGROUND: Subcutaneous (SC) vedolizumab is effective in inflammatory bowel diseases (IBD) when administered after induction with two infusions. AIM: To assess the effectiveness, safety and pharmacokinetics of a switch from intravenous (IV) to SC maintenance vedolizumab in patients with IBD METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Volkers, Adriaan, Straatmijer, Tessa, Duijvestein, Marjolijn, Sales, Amber, Levran, Amit, van Schaik, Fiona, Maljaars, Jeroen, Gecse, Krisztina, Ponsioen, Cyriel, Grootjans, Joep, Hanzel, Jurij, Tack, Greetje, Jansen, Jeroen, Hoentjen, Frank, de Boer, Nanne, van der Marel, Sander, Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van der Meulen, Andrea, D′Haens, Geert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Route of Vedolizumab Administration in IBD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540102/
https://www.ncbi.nlm.nih.gov/pubmed/35869807
http://dx.doi.org/10.1111/apt.17153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540102/
https://www.ncbi.nlm.nih.gov/pubmed/35869807
http://dx.doi.org/10.1111/apt.17153

Ejemplares similares